Navigation Links
Common osteoporosis drugs are associated with a decrease in risk of breast cancer
Date:3/2/2010

SEATTLE Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer.

The study found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zomita, for more than two years had a nearly 40 percent reduction in risk as compared to those who did not, according to lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program at Fred Hutchinson Cancer Research Center.

"This large study provides new evidence that the use of bisphosphonates is associated with a potentially important reduction in breast cancer risk," Newcomb said.

The protective effect was observed only among women who were not obese. "Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk," Newcomb said.

The way in which these drugs may prevent breast cancer is not known, but several research observations may be relevant. "These drugs may affect cell function and be important in cell growth and death specifically the death of tumors or even premalignant disease," Newcomb said. Researchers have found that some kinds of bisphosphonates directly cause tumor apoptosis (cellular suicide), inhibit angiogenesis (prevent tumors from establishing a blood supply) and prevent tumor-cell adhesion (the ability of cancer cells to bind to one another).

The study involved nearly 6,000 Wisconsin women, aged 20 to 69. Half had been diagnosed with invasive breast cancer and, for comparison purposes, half had not. The women were interviewed about their bone health their history of fractures, whether they'd been diagnosed with osteoporosis and their history of bisphosphonate use.

Breast cancer risk factors such as first-degree family history of the disease, age at first birth, postmenopausal hormone use and body mass index were accounted for in the analysis. "Because we were able to account for important cofounders, these findings may reflect real benefits due to the anti-tumor mechanisms of these medications," the authors wrote.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
2. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
3. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
4. Migraine More Common in Women with MS
5. New therapeutic target for most common solid cancer in childhood?
6. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
7. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
8. A common cholesterol drug fights cataracts, too
9. Adapting to clogged airways makes common pathogen resist powerful drugs
10. Metabolite common among cancers
11. Nutrition Management Services Company Announces Decision to Deregister its Class A Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... , ... Scientists from the University of Exeter reported this month ... equivalent to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal ... spine care, I understand the importance exercise can play on improving bone health. Although ...
(Date:7/23/2017)... Fla. (PRWEB) , ... July 23, 2017 , ... ... M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned by ... board certification in interventional pain management, Dr. Stern also is certified in pediatrics, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology: